Table 13.6a

Immunosuppression Use for Induction, 1993 to 2002

Recipients with Heart-Lung Transplants

	Year of Transplant
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants	60	71	69	39	61	47	51	48	27	32
Tx With Immunosuppression Info	58	68	69	35	58	45	50	48	26	32
No Induction Drugs Recorded	87.9%	70.6%	50.7%	65.7%	70.7%	75.6%	66.0%	47.9%	26.9%	40.6%
Drugs	-	0.0%	0.0%	-	-	-	-	-	-	-
ALG
ATG	-	22.1%	43.5%	22.9%	24.1%	15.6%	10.0%	27.1%	26.9%	15.6%
NRATG/NRATS	-	-	-	5.7%	1.7%	4.4%	6.0%	2.1%	-	-
OKT3	12.1%	7.4%	7.2%	8.6%	6.9%	6.7%	10.0%	6.3%	-	6.3%
Thymoglobulin	-	-	-	-	-	-	4.0%	4.2%	11.5%	3.1%
Zenapax	-	-	-	-	-	-	4.0%	12.5%	7.7%	15.6%
Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.2%	30.8%	18.8%

Source: OPTN/SRTR Data as of August 1, 2003.

(-) = Drug not used anytime during the year.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.